Ublituximab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis

Journal: Ideggyogyaszati szemle

Published: March 28, 2026

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.

Journal: JAMA neurology

Published: February 16, 2026

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Journal: Handbook of clinical neurology

Published: January 12, 2026

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Journal: Neurology and therapy

Published: December 16, 2025

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

Journal: Frontiers in immunology

Published: November 03, 2025

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis.

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis.

Journal: Cureus

Published: October 25, 2025

Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.

Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.

Journal: Therapeutic advances in neurological disorders

Published: October 15, 2025

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies.

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies.

Journal: Expert opinion on drug safety

Published: October 13, 2025

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.

Journal: Therapeutic advances in neurological disorders

Published: October 02, 2025

Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.

Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers.

Journal: Inflammopharmacology

Published: September 23, 2025

Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports.

Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports.

Journal: Iranian journal of pharmaceutical research : IJPR

Published: September 20, 2025

A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis.

A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis.

Journal: Therapeutic advances in neurological disorders

Published: August 29, 2025

Showing 1-12 of 106

Last Updated: 04/28/2026